Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine

摘要

Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F at a dose of 75mg/m 2 /daily subcutaneously for 7days every 28days. Hematologic improvements were observed according to the International Working Group 2006 criteria after 8 cycles of the azacitidine treatment, and complete remission was achieved after 14 cycles. The grade of myelofibrosis was also improved. The therapeutic activity of azacitidine was confirmed in our MDS-F patient. Highlights ? We here reported the successful response of a MDS-F patient treated with azacitidine. ? Complete remission was achieved after 14 cycles of the azacitidine treatment. ? The grade of myelofibrosis was improved significantly. ? Tri-lineage dysplasia with severe dysmegakaryopoiesis still remains. ? The therapeutic activity of azacitidine was confirmed in our MDS-F patient.